Creation of combined stabilizing compositions to preserve the activity of gonadotropins in liquid form

O. V. Shtapenko¹, I. I. Gevkan¹, V. Y. Syrvatka², O. Y. Slyvchuk¹, O. O. Korbetska¹, S. B. Kornyat¹, I. M. Yaremchuk¹

¹Institute of Animal Biology NAAS,
38 V. Stusa str., Lviv, 79034, Ukraine, This email address is being protected from spambots. You need JavaScript enabled to view it.

²Ivan Franko National University of Lviv,
4 M. Hrushevskoho str., Lviv, 79005, Ukraine

The activity of dissolved enzyme preparations during storage decreases, what leads to the loss of their biological activity and, as a result, reduces the effectiveness of the drugs. Therefore, the development of compositions that are able to maintain high activity of the hormone in dissolved form during long-term storage is relevant. The results of studies have shown that using sucrose as a stabilizing component for maintain gonadotropin activity is effective. It was found that during eight weeks of storage the best results on the preservation of gonadotropin activity during storage at 40°C were obtained in samples containing 75 mg/ml of sucrose compared to the sample of the control group. However, the highest gonadotropin activity was found when — 10 mg/ml L-lysine and 75 mg/ml sucrose were used as stabilizers. Studies of the dynamics of gonadotropin activity during long-term storage at 18–20°C showed that the addition of L-lysine and sucrose as stabilizing substances in the form of liposomal emulsion increases the preservation of chorionic hormone activity for 2 weeks of storage by 11.4% compared to similar composition pharmacological composition of the drug in aqueous form.

Key words: human chorionic hormone, activity, stabilization, sucrose, mannitol, lysine

1. Agostinetto R, Samaritani F. Del Rio A, Richard J. LH liquid formulations. Patent for invention no. US-8664369-B2 from 04.03.2014. Available at: https://pubchem.ncbi.nlm.nih.gov/patent/US-8664369-B2
2. Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: distinguishing unique physiologic roles. Endocrinol. 2014; 30 (3): 174–181. DOI: 10.3109/09513590.2013.859670.
3. Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: origins of difference. Cell Endocrinol. 2014; 383 (1–2): 203–213. DOI: 10.1016/j.mce.2013.12.009.
4. Chu C, Li L, Li S, Li M, Ge S, Yu J, Yan M, Song X. Fluorescence-based immunoassay for human chorionic gonadotropin based on polyfluorene-coated silica nanoparticles and polyaniline-coated Fe₃O₄ Microchim. Acta. 2013; 180: 1509–1516. https://doi.org/10.1007/s00604-013-1067-7.
5. Fernández-Tejada A, Vadola PA, Danishefsky SJ. Chemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormones. Am. Chem. Soc. 2014; 136 (23): 8450-8458. DOI: 10.1021/ja503545r.
6. Fournier T. Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production. Endocrinol. (Paris). 2016; 77 (2): 75–81. DOI: 10.1016/j.ando.2016.04.012.
7. Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Steril. 2014; 102 (2): 405–409. DOI: 10.1016/j.fertnstert.2014.04.028.
8. Lawrenz B, Samir S, Garrido N, Melado L, Engelmann N, Fatemi H. Luteal coasting and individualization of human chorionic gonadotropin dose after gonadotropin-releasing hormone agonist triggering for final oocyte maturation — a retrospective proof-of-concept study. Endocrinol. 2018; 9: 33. DOI: 10.3389/fendo.2018.00033.
9. Odintsova V, Bidnenko O. Selection of the excipients to create tablets of adamantane-1-ammonium 2-((5-(adamantane-1-yl)-4-phenyl-4h-1,2,4-triazole-3-yl)thio)acetate by the method of wet granulation. Part 1. ScienceRise: Pharm. Sci. 2017; 1 (5): 49–53. DOI: 10.15587/2519-4852.2017.93722.
10. Pertsev I, Dmitrievsky, Rybachuk V. Excipients in Drug Technology: the impact on technological, consumer, economic characteristics and therapeutic efficacy. A textbook for students. Kharkiv, Golden Pages, 2010: 600 p. ISBN 978-966-400-178-3. (in Ukrainian)
11. Schanz A, Lukosz M, Hess AP, Baston-Büst DM, Krüssel JS, Heiss C. hCG stimulates angiogenic signals in lymphatic endothelial and circulating angiogenic cells. Reprod. Immunol. 2015; 110: 102–108. DOI: 10.1016/j.jri.2015.01.011.
12. Slyvchuk Y, Matiukha I, Syrvatka V, Hevkan I, Shtapenko O, Broda N. The influence of physical and chemical factors on HCG conservation activity for a long stored in the dilution state. ScienceRise: Biol. Sci. 2015; 11 (6/16): 18–22. DOI: 10.15587/2313-8416.2015.53805.
13. Stolzenberger S., Kohler E. Liquid formulation of FSH. Patent for invention no. CN-101970010-A from 09.02.2011. Available at: https://testpubchem.ncbi.nlm.nih.gov/patent/CN-101970010-A